Most Recent
The High Court has found that Novartis unit Sandoz infringed Danish drug company Lundbeck's patent for its blockbuster antidepressant Lexapro, but has overturned a ruling that found the generic drug maker owes $26.3 million in damages.
A toy designer that has been sued for allegedly copying the design of toy maker Jellycat’s beloved ‘Bashful Bunny’ has pushed back at a request for discovery concerning its design process, telling the court “a plush toy in the shape of a bunny is hardly a revolutionary concept”.
Bristol-Myers Squibb unit Celgene has dropped a lawsuit accusing Indian generics company Dr Reddy's Laboraties of threatening to infringe its patent for Revlimid with the planned launch of a generic version of the blockbuster cancer drug in Australia.
Tech company Vehicle Management Systems has come up short in its third attempt to block competitor SARB Management Group's patent application for a magnetic parking overstay detector, with the Full Court rejecting claims that VMS' managing director should have been listed as the device's inventor.
Indian generics giant Dr Reddy’s Laboratories must give Bristol-Myers Squib unit Celgene Corporation three months’ notice before deciding to sell generic versions of blockbuster cancer drug Revlimid in Australia.
Generic drug maker Sandoz AG has filed proceedings seeking the revocation of two patents registered in Australia by German pharmaceutical giant Bayer covering its top-selling blood clot drug Xarelto.
Bristol-Myers Squib unit Celgene Corporation has sued Indian generics giant Dr Reddy’s Laboratories for allegedly threatening to infringe eight patents for its blockbuster cancer drug Revlimid, which raked in US$12 billion for the US-based company in revenue last year.
The Federal Court's decision that artificial intelligence can be listed on a patent application as the inventor has become an outlier, as the UK joins the US in rejecting what has become an international battle to claim AI inventorship.
An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drug was wrongly granted.
Merck Sharp & Dohme is seeking to overturn a judgment refusing an extension of a patent covering its Januvia and Janumet diabetes drugs that would have seen the US drug maker of retaining a monopoly over the multibillion dollar medicines beyond July 2022.